SH2D3C and renal carcinoma: Additionally, we found that the binding site of Sunitinib (CHEMBL1567), a therapeutic used to treat renal cancer, to its target (vascular endothelial growth factor receptor 2) has a strong similarity to the ADP-ribose binding site of CHIKV nsP3.